UP!

AZN $54.28   View long term graphs

AstraZeneca plc
Type
Public limited company
Traded as LSE: AZN
Nasdaq Stockholm: AZN
NYSE: AZN
FTSE 100 Component
Industry Pharmaceutical
Biotechnology
Predecessor Astra AB
Zeneca Group plc
Founded April 6, 1999; 18 years ago (1999-04-06)
Headquarters Cambridge, England
Area served
Global
Key people
Leif Johansson (Chairman)
Pascal Soriot (CEO)
Products Pharmaceutical products
Revenue Decrease US$23.002 billion (2016)
Operating income
Increase US$4.902 billion (2016)
Net income
Increase US$3.406 billion (2016)
Total assets Increase US$60.12 billion (2016)
Number of employees
50,000 (2014)
Subsidiaries MedImmune
Website www.astrazeneca.com

AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.

The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).

AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.

Astra AB was founded in 1913 in Södertälje, Sweden, by 400 doctors and apothecaries. In 1993 the British chemicals company ICI demerged its pharmaceuticals businesses and its agrochemicals and specialties businesses, to form Zeneca Group plc. Finally, in 1999 Astra and Zeneca Group merged to form AstraZeneca plc, with its headquarters in London. In 1999, AstraZeneca identified as a new location for the company's US base the "Fairfax-plus" site in North Wilmington, Delaware.

In 2002, its drug Iressa was approved in Japan as monotherapy for non-small cell lung cancer. On 3 January 2004 Dr Robert Nolan, a former director of AstraZeneca, formed the management team of ZI Medical.

In 2005, the company acquired KuDOS Pharmaceuticals, a UK biotech company, for £120m and entered into an anti-cancer collaboration agreement with Astex. It also announced that it had become a Diamond Member of the Pennsylvania Bio commerce organisation.

In 2006, following a collaborative relationship begun in 2004, AstraZeneca acquired Cambridge Antibody Technology for £702 million.

In February 2007, AstraZeneca agreed to buy Arrow Therapeutics, a company focused on the discovery and development of anti-viral therapies, for $150 million. AstraZeneca's pipeline, and "patent cliff", was the subject of much speculation in April 2007 leading to pipeline-boosting collaboration and acquisition activities. A few days later AstraZeneca acquired US company MedImmune for about $15.2 billion to gain flu vaccines and an anti-viral treatment for infants; AstraZeneca subsequently consolidated all of its biologics operations into a dedicated biologics division called MedImmune.

In 2010, AstraZeneca acquired Novexel Corp, an antiobiotics discovery company formed in 2004 as a spin-off of the Sanofi-Aventis anti-infectives division. Astra acquired the experimental antibiotic NXL-104 (CEF104) (CAZ-AVI) through this acquisition.

In 2011, AstraZeneca acquired Guangdong BeiKang Pharmaceutical Company, a Chinese generics business.

In February 2012, AstraZeneca and Amgen announced a collaboration on treatments for inflammatory diseases. Then in April 2012, AstraZeneca acquired Ardea Biosciences, another biotechnology company, for $1.26 billion. In June 2012, AstraZeneca and Bristol-Myers Squibb announced a two-stage deal for the joint acquisition of the biotechnology company Amylin Pharmaceuticals. It was agreed that Bristol-Myers Squibb would acquire Amylin for $5.3 billion in cash and the assumption of $1.7 billion in debt, with AstraZeneca then paying $3.4 billion in cash to Bristol-Myers Squibb, and Amylin being folded into an existing diabetes joint-venture between AstraZeneca and Bristol-Myers Squibb.

In March 2013 AstraZeneca announced plans for a major corporate restructuring, including the closure of its research and development activities at Alderley Park, investment of $500 million in the construction of a new research and development facility in Cambridge and the concentration of R&D in three locations: Cambridge, Gaithersburg, Maryland (location of MedImmune, where it will work on biotech drugs), and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. AstraZeneca also announced that it would move its corporate headquarters from London to Cambridge in 2016. That announcement included the announcement that it would cut 1,600 jobs; three days later it announced it would cut an additional 2,300 jobs. It also announced that it would focus on three therapeutic areas: Respiratory, Inflammation & Autoimmunity; Cardiovascular & Metabolic Disease; and Oncology. In October 2013, AstraZeneca announced it would acquire biotech oncology company Spirogen for around $440 million.

On 19 May 2014 AstraZeneca rejected a "final offer" from Pfizer of £55 per share, which valued the company at £69.4 billion ($117 billion). The companies had been meeting since January 2014. If the takeover had proceeded Pfizer would have become the world's biggest drug maker. The transaction would also have been the biggest foreign takeover of a British company. Many in Britain, including politicians and scientists, had opposed the deal. In July 2014 the company entered into a deal with Almirall to acquire its subsidiary Almirall Sofotec and its lung treatments including the COPD drug, Eklira. The $2.1 billion deal included an allocation of $1.2 billion for development in the respiratory franchise, one of AstraZeneca's three target therapeutic areas announced the year before. In August 2014 the company announced it had entered into a three-year collaboration with Mitsubishi Tanabe Pharma on diabetic nephropathy. In September 2014 the company would join forces with Eli Lilly in developing and commercialising its candidate BACE inhibitor – AZD3292 – used for the treament of Alzheimers. The deal could yield up to $500 million for the company. In November 2014 the company's biologics R&D operation, MedImmune, agreed to acquire Definiens for more than $150 million. The company also began a Phase I/II trial collaboration with Pharmacyclics and Janssen Biotech investigating combination treatments. Also in November of the same year, the company agreed to sell its lipodystrophy treatment business to Aegerion Pharmaceuticals for more than $325 million. In December, the company received accelerated FDA approval for Olaparib in the treatment of women with advanced ovarian cancer who have a BRCA genetic mutation. A major criterion governing the drugs approval was, on average, its ability to shrink tumours in patients for 7.9 months.

In February, the company announced it would acquire the US and Canadian rights to Actavis' branded respiratory drug business for an initial sum of $600 million. Later in the same month the company announced it would partner with Orca Pharmaceuticals to develop retinoic acid–related orphan nuclear receptor gamma inhibitors for use in the treatment of a number of autoimmune diseases, which could generate up to $122.5 million for Orca. The company also announced their plan to spend $40 million creating a new subsidiary focused on small molecule anti-infectives - primarily in the research of the gyrase inhibitor, AZD0914, which is currently in Phase II for the treatment of gonorrhea. The company underwrote twenty out of thirty-two seats of a new Cambridge-Gothenburg service by Sun-Air of Scandinavia

In mid-March the company announced it would co commercialise naloxegol along with Daiichi Sankyo in a deal worth up to $825 million. Towards the end of April the company announced a number of collaborations worth an estimated $1.8 billion; firstly, to develop and commercialise MEDI4736, with Celgene, for use against non-Hodgkin’s lymphoma, myelodysplastic syndromes, and multiple myeloma with AstraZeneca receiving $450 million. The second of two-deals is an agreement to study a combination treatment of MEDI4736 and Innate Pharma’s Phase II anti-NKG2A antibody IPH2201 for up to $1.275 billion. The company's Medimmune arm also launched collaborative clinical trials with Juno Therapeutics, investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno Therapeutics' CD19 directed chimeric antigen receptor T-cell candidates. In late June the company announced it has entered into a partnership agreement with Eolas Therapeutics on the Eolas Orexin-1 Receptor Antagonist (EORA) program for smoking cessation and other treatments. In July the company announced it would sell off its rights to Entocort (budesonide) to Tillotts Pharma for $215 million. In July 2015, Genzyme announced it would acquire the rare cancer drug Caprelsa (vandetanib) from AstraZeneca for up to $300 million. In August, the company announced it has acquired the global rights to develop and commercialise Heptares Therapeutics drug candidate HTL-1071, which focuses on blocking the adenosine A2A receptor, in a deal worth up to $510 million. In the same month the company's MedImmune subsidiary acquire exclusive rights to Inovio Pharmaceuticals INO-3112 immunotherapy, currently in Phase I/II, under an agreement which could net more than $727.5 million for Inovio. INO-3112 targets Human papillomavirus types 16 and 18. In September, Valeant licensed Brodalumab from the company for up to $445 million. On the 6th of November it was reported that AstraZeneca acquired ZS Pharma for $2.7 billion. In December the company announced its intention to acquire the respiratory portfolio of Takeda Pharmaceutical - namely Alvesco and Omnaris - for $575 million A day later, the company announced it had taken a 55% majority stake in Acerta for $4 billion. As part of the transaction the company will gain commercial rights to Acerta's irreversible oral Bruton's tyrosine kinase inhibitor, acalabrutinib (ACP-196), which is currently in Phase III development for B-cell blood cancers and in Phase I or II clinical trials in solid tumours. In 2015, it was the eighth-largest drug company in the world based on sales revenue.

In July 2017, the company's CEO Pascal Soriot said that Brexit would not affect its commitment to its current plans in the United Kingdom. However, it had slowed decision making for new investment projects waiting for post-Brexit regulatory regime to settle down. In September 2017, the company's chairman Leif Johansson planned in taking "first steps" in moving their research and manufacturing, operations away from the United Kingdom, If there is a hard Brexit. In 2017, it was the eleventh-largest drug company in the world based on sales and ranked seventh based on R&D investment.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

Astra
(Founded 1913)

Tika
(Acq 1939)

Zeneca
(Spun off from Imperial Chemical Industries 1993)

Salick Health Care
(Acq 1996)

Ishihara Sangyo Kaisha
(US fungicide operations, Acq 1997)

KuDOS Pharmaceuticals
(Acq 2005)

Cambridge Antibody Technology
(Acq 2006)

Aptein Inc
(Acq 1998)

Arrow Therapeutics
(Acq 2007)

MedImmune
(Acq 2007)

Definiens
(Acq 2014)

Novexel Corp
(Acq 2010)

Guangdong BeiKang Pharmaceutical Company
(Acq 2011)

Ardea Biosciences
(Acq 2012)

Amylin Pharmaceuticals
(Acq 2012 jointly with Bristol-Myers Squibb )

Spirogen
(Acq 2013)

Pearl Therapeutics
(Acq 2013)

Omthera Pharmaceuticals
(Acq 2013)

Bought out Bristol-Myers Squibb's share of joint diabetes assets, 2013

Entasis Therapeutics
(Spun off 2015)

ZS Pharma
(Acq 2015)

AstraZeneca develops, manufactures and sells pharmaceutical and biotechnology products to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.

AstraZeneca has its corporate headquarters in London, England, and its research and development (R&D) headquarters are in Södertälje, Sweden and in Warsaw, Poland. The company employs over 11,000 people at research facilities in the United Kingdom, United States, Sweden, France, Canada, India, China, Brazil and Japan.

The company's largest single research and development site is at Alderley Park, a large country estate in Cheshire, England. Around 4,500 staff are based at the site.

The company has a major research and development presence in Sweden, with approximately 4,000 staff employed at research facilities in Mölndal and Södertälje.

The following products are found on the AstraZeneca website. Generic drug names are given in parentheses following the brand name.

– Anesthetics

– Cardiovascular

– Diabetes

– Gastrointestinal

– Infectious diseases

– Neuroscience

– Oncology

– Respiratory and inflammatory diseases

In April 2015, AstraZeneca's drug tremelimumab was approved as an orphan drug for the treatment of mesothelioma in the United States. In February 2016, AstraZeneca announced that a clinical trial of tremelimumab as a treatment for mesothelioma failed to meet its primary endpoint.

As of 2008, David Brennan was paid $1,574,144 for his role as chief executive officer.

On 26 April 2012 it was announced that Brennan was to retire early in the June of that year In August 2012, Pascal Soriot was named CEO of AstraZeneca.

"It was also announced that Leif Johansson will succeed Louis Schweitzer as Non-Executive chairman on 1 June 2012 – three months earlier than previously announced – and will become Chairman of the Nomination and Governance Committee after (the 2012) Annual General Meeting."

In April 2010 AstraZeneca settled a qui tam lawsuit brought by Stefan P. Kruszewski for $520 million to settle allegations that the company defrauded Medicare, Medicaid, and other government-funded health care programs in connection with its marketing and promotional practices for the blockbuster atypical antipsychotic, Seroquel.

In March 2011, AstraZeneca settled a lawsuit in the United States totalling $68.5 million to be divided up to 38 states.

The company's most commercially successful medication is esomeprazole (Nexium). The primary uses are treatment of gastroesophageal reflux disease, treatment and maintenance of erosive esophagitis, treatment of duodenal ulcers caused by Helicobacter pylori, prevention of gastric ulcers in those on chronic NSAID therapy, and treatment of gastrointestinal ulcers associated with Crohn's disease. When it is manufactured the result is a mixture of two mirror-imaged molecules, R and S. Two years before the omeprazole patent expired, AstraZeneca patented S-omeprazole in pure form, pointing out that since some people metabolise R-omeprazole slowly, pure S-omeprazole treatment would give higher dose efficiency and less variation between individuals. In March 2001, the company began to market Nexium, as it would a brand new drug.

The (R)-entantiomer of omeprazole is metabolized exclusively by the enzyme CYP2C19, which is expressed in very low amounts by 3% of the population. Treated with a normal dose of the enantiomeric mixture, these persons will experience blood levels five-times higher than those with normal CYP2C19 production. In contrast, esomeprazole is metabolized by both CYP2C19 and CYP3A4, providing less-variable drug exposure. While omeprazole is approved only at doses of up to 20 mg for the treatment of gastroesophageal reflux, esomeprazole is approved for doses up to 40 mg.

In 2007, Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a lecturer in social medicine at the Harvard Medical School, said in Stern, a German-language weekly newsmagazine, that AstraZeneca's scientists had misrepresented their research on the drug's efficiency, saying "Instead of using presumably comparable doses [of each drug], the company's scientists used Nexium in higher dosages. They compared 20 and 40 mg Nexium with 20 mg Prilosec. With the cards having been marked in that way, Nexium looked like an improvement – which however was only small and shown in only two of the three studies."

On 4 February 1998, Astra USA sued Lars Bildman, its former president and chief executive officer, seeking $15 million for defrauding the company. The sum included $2.3 million in company funds he allegedly used to fix up three of his homes, plus money the company paid as the result of the EEOC investigation. Astra's lawsuit alleged Bildman sexually harassed and intimidated employees, used company funds for yachts and prostitutes, destroyed documents and records, and concocted "tales of conspiracy involving ex-KGB agents and competitors. This was in a last-ditch effort to distract attention from the real wrongdoer, Bildman himself." Bildman had already pleaded guilty in US District Court for failing to report more than $1 million in income on his tax returns; in addition, several female co-workers filed personal sexual-harassment lawsuits.

In 2010 AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing.

On July 27, 2015, Fabio Taborre (Androni-Sidermec) returned a positive doping test result for the banned blood-booster FG-4592 in an out-of-competition control on June 16, 2015. FG-4592 (Roxadustat) is in phase 3 clinical trials and has not yet been commercialised. The drug was developed jointly by FibroGen and AstraZeneca. Unlike Erythropoietin (EPO), which directly stimulates the production of red blood cells, FG-4592 is taken orally, and stimulates natural production of EPO in a manner similar to altitude training.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-11 Future report Set alerts
Q3 2020 2020-11-05 0.00 0.00
Q2 2020 2020-07-30 0.48 0.29
Q1 2020 2020-04-29 0.53 0.30
Q4 2019 2020-02-14 0.45 0.12
Q3 2019 2019-10-24 0.50 0.12
Q2 2019 2019-07-25 0.37 0.05
Q1 2019 2019-04-26 0.45 0.24
Q4 2018 2019-02-14 0.79 0.41
Q3 2018 2018-11-12 0.35 0.17

Ratings

2016-07-12 Initiated Coverage Argus Hold
2016-06-27 Reiterated Rating Deutsche Bank Buy
2016-06-27 Reiterated Rating Deutsche Bank AG Buy
2016-06-25 Reiterated Rating Citigroup Inc. Buy
2016-06-16 Reiterated Rating Leerink Swann Hold $34.00
2016-06-14 Reiterated Rating Shore Capital Hold
2016-06-07 Reiterated Rating Deutsche Bank Buy
2016-06-06 Reiterated Rating Jefferies Group Hold
2016-05-31 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-05-31 Reiterated Rating Beaufort Securities Hold
2016-05-27 Reiterated Rating Goldman Sachs Sell
2016-05-27 Reiterated Rating Goldman Sachs Group Inc. Sell
2016-05-25 Reiterated Rating Citigroup Inc. Buy
2016-05-23 Reiterated Rating Deutsche Bank Buy
2016-05-19 Reiterated Rating Bank of America Buy
2016-05-19 Reiterated Rating Bank of America Corp. Buy
2016-05-18 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-05-17 Reiterated Rating Shore Capital Hold
2016-05-16 Reiterated Rating Deutsche Bank Buy
2016-05-03 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-05-03 Reiterated Rating Bank of America Buy
2016-05-02 Lower Price Target Leerink Swann Market Perform $38.00 to $34.00
2016-04-21 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-04-20 Reiterated Rating Jefferies Group Hold
2016-04-17 Reiterated Rating Leerink Swann Hold
2016-04-11 Downgrade Goldman Sachs Neutral to Sell
2016-04-11 Reiterated Rating Beaufort Securities Hold
2016-04-01 Reiterated Rating Citigroup Inc. Buy
2016-03-31 Reiterated Rating Beaufort Securities Hold
2016-03-24 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-03-24 Reiterated Rating Bank of America Buy
2016-03-15 Downgrade Jefferies Group Buy to Hold $28.29 to $29.35
2016-02-28 Initiated Coverage Drexel Hamilton Buy
2016-02-26 Initiated Coverage Cantor Fitzgerald Buy
2016-02-20 Reiterated Rating Beaufort Securities Hold
2016-02-16 Reiterated Rating Deutsche Bank Buy
2016-02-08 Downgrade HSBC Buy to Hold
2016-02-05 Reiterated Rating Beaufort Securities Hold
2016-02-05 Lower Price Target Sanford C. Bernstein $34.00 to $32.00
2016-02-05 Reiterated Rating JPMorgan Chase & Co. Neutral
2016-02-05 Reiterated Rating Goldman Sachs Neutral
2016-02-02 Reiterated Rating Leerink Swann Market Perform $37.00 to $38.00
2016-01-26 Upgrade Oddo & Cie Neutral to Top Pick
2016-01-26 Upgrade Oddo Securities Neutral to Top Pick
2016-01-19 Upgrade Barclays Underweight to Equal Weight $44.00 to $50.00
2016-01-19 Upgrade Barclays PLC Underweight to Equal Weight $44.00 to $50.00
2016-01-13 Reiterated Rating Deutsche Bank Buy
2016-01-13 Reiterated Rating Credit Suisse Underperform
2016-01-13 Reiterated Rating Credit Suisse Group AG Underperform
2015-12-30 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-12-30 Reiterated Rating Morgan Stanley Buy
2015-12-24 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-12-24 Reiterated Rating Morgan Stanley Buy
2015-12-18 Reiterated Rating Morgan Stanley Buy
2015-12-18 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-12-17 Reiterated Rating Leerink Swann Hold $37.00
2015-12-07 Reiterated Rating Morgan Stanley Buy
2015-12-01 Upgrade Morgan Stanley Underweight to Overweight
2015-11-30 Reiterated Rating BNP Paribas Outperform
2015-11-18 Reiterated Rating Goldman Sachs Neutral
2015-11-09 Reiterated Rating Beaufort Securities Hold
2015-11-09 Reiterated Rating Leerink Swann In-Line to Market Perform $37.00
2015-11-08 Reiterated Rating Morgan Stanley Sell
2015-11-02 Downgrade Nordea Equity Research Buy to Hold
2015-10-27 Reiterated Rating Beaufort Securities Hold
2015-10-22 Reiterated Rating Morgan Stanley Sell
2015-10-21 Lower Price Target Sanford C. Bernstein $38.00 to $34.00
2015-10-20 Downgrade Credit Suisse Neutral to Underperform
2015-10-15 Reiterated Rating Bank of America Buy
2015-09-28 Reiterated Rating Deutsche Bank Buy
2015-09-23 Reiterated Rating Citigroup Inc. Buy
2015-09-18 Upgrade Bryan Garnier & Cie Neutral to Buy
2015-09-18 Upgrade Bryan, Garnier & Co Neutral to Buy
2015-09-14 Upgrade Deutsche Bank Hold to Buy
2015-09-14 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-09-08 Reiterated Rating Citigroup Inc. Buy
2015-09-02 Upgrade HSBC Hold to Buy
2015-07-31 Upgrade S&P Equity Research Buy $38.00
2015-07-31 Upgrade Swedbank Neutral to Buy
2015-07-02 Upgrade Berenberg Bank Hold to Buy
2015-06-25 Initiated Coverage HSBC Hold
2015-06-09 Reiterated Rating Deutsche Bank Hold
2015-06-02 Reiterated Rating Kepler Capital Markets Reduce
2015-06-02 Reiterated Rating BNP Paribas Outperform
2015-06-01 Reiterated Rating Jefferies Group Buy
2015-05-27 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-05-27 Reiterated Rating Citigroup Inc. Buy
2015-05-27 Reiterated Rating Beaufort Securities Hold
2015-05-26 Reiterated Rating Deutsche Bank Hold
2015-05-15 Reiterated Rating BNP Paribas Outperform
2015-05-15 Reiterated Rating Deutsche Bank Hold
2015-05-14 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-05-14 Reiterated Rating Barclays Underweight
2015-05-12 Reiterated Rating Credit Suisse Neutral
2015-04-29 Reiterated Rating Citigroup Inc. Buy
2015-04-27 Reiterated Rating Deutsche Bank Hold
2015-04-24 Reiterated Rating Credit Suisse Buy
2015-04-24 Reiterated Rating Jefferies Group Buy
2015-04-24 Reiterated Rating Berenberg Bank Hold
2015-04-21 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-04-16 Reiterated Rating Liberum Capital Buy
2015-04-16 Reiterated Rating Credit Suisse Neutral
2015-04-16 Reiterated Rating Citigroup Inc. Buy
2015-04-16 Reiterated Rating Beaufort Securities Hold
2015-04-16 Reiterated Rating Barclays Underweight
2015-04-15 Reiterated Rating Kepler Capital Markets Reduce
2015-04-15 Reiterated Rating Deutsche Bank Hold
2015-04-15 Initiated Coverage Societe Generale Buy
2015-04-13 Reiterated Rating Shore Capital Buy
2015-04-13 Reiterated Rating Jefferies Group Buy
2015-04-08 Reiterated Rating BNP Paribas Outperform
2015-03-31 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-03-17 Reiterated Rating BNP Paribas Outperform
2015-03-17 Reiterated Rating Beaufort Securities Hold
2015-03-16 Reiterated Rating Shore Capital Buy
2015-03-16 Reiterated Rating Kepler Capital Markets Reduce
2015-03-12 Reiterated Rating Deutsche Bank Hold
2015-03-10 Reiterated Rating JPMorgan Chase & Co. Neutral
2015-03-10 Reiterated Rating Jefferies Group Buy
2015-03-06 Reiterated Rating Barclays Underweight
2015-03-05 Reiterated Rating Citigroup Inc. Buy
2015-02-25 Reiterated Rating Citigroup Inc. Buy
2015-02-24 Reiterated Rating Kepler Capital Markets Reduce
2015-02-24 Reiterated Rating Credit Suisse Neutral
2015-02-20 Reiterated Rating Jefferies Group Buy
2015-02-17 Reiterated Rating Beaufort Securities Hold
2015-02-13 Reiterated Rating Credit Suisse Neutral
2015-02-10 Reiterated Rating Barclays Underweight
2015-02-06 Reiterated Rating Panmure Gordon Buy
2015-02-06 Reiterated Rating Deutsche Bank Hold
2015-02-06 Reiterated Rating Beaufort Securities Hold
2015-02-06 Downgrade Danske Sell
2015-02-05 Reiterated Rating Liberum Capital Buy
2015-02-05 Reiterated Rating Jefferies Group Buy
2015-02-05 Reiterated Rating Berenberg Bank Hold
2015-02-04 Reiterated Rating Citigroup Inc. Buy
2015-02-03 Upgrade SEB Equity Research Hold to Buy
2015-01-30 Reiterated Rating BNP Paribas Outperform
2015-01-28 Reiterated Rating Deutsche Bank Hold
2015-01-27 Reiterated Rating Shore Capital Buy
2015-01-22 Boost Price Target Leerink Swann $38.00 to $38.50
2015-01-21 Reiterated Rating Credit Suisse Neutral
2015-01-16 Downgrade Barclays Equal Weight to Underweight
2015-01-14 Reiterated Rating Berenberg Bank Hold
2015-01-12 Reiterated Rating Citigroup Inc. Buy
2015-01-09 Reiterated Rating Credit Suisse Neutral
2015-01-05 Upgrade JPMorgan Chase & Co. Underweight to Neutral
2014-12-17 Reiterated Rating Liberum Capital Buy
2014-12-10 Reiterated Rating Beaufort Securities Hold
2014-12-09 Reiterated Rating JPMorgan Chase & Co. Underweight
2014-12-04 Reiterated Rating Jefferies Group Buy
2014-12-02 Reiterated Rating Citigroup Inc. Buy
2014-12-02 Downgrade Morgan Stanley Equal Weight to Underweight
2014-11-28 Reiterated Rating Credit Suisse Neutral
2014-11-25 Initiated Coverage BNP Paribas Outperform
2014-11-24 Reiterated Rating Deutsche Bank Hold
2014-11-19 Reiterated Rating Citigroup Inc. Buy
2014-11-18 Reiterated Rating JPMorgan Chase & Co. Underweight
2014-11-18 Reiterated Rating Credit Suisse Neutral
2014-11-17 Reiterated Rating Barclays Equal Weight
2014-11-13 Reiterated Rating Beaufort Securities Hold
2014-11-12 Reiterated Rating Deutsche Bank Hold
2014-11-07 Reiterated Rating Credit Suisse Neutral
2014-11-06 Reiterated Rating Panmure Gordon Buy
2014-11-06 Reiterated Rating Jefferies Group Buy
2014-11-06 Reiterated Rating Berenberg Bank Hold
2014-11-05 Reiterated Rating Beaufort Securities Hold
2014-11-03 Reiterated Rating Deutsche Bank Hold
2014-10-31 Reiterated Rating Citigroup Inc. Buy
2014-10-16 Reiterated Rating Deutsche Bank Hold
2014-10-16 Reiterated Rating Credit Suisse Neutral
2014-10-14 Upgrade Bank of America Neutral to Buy
2014-10-13 Upgrade Jefferies Group Hold to Buy
2014-10-07 Reiterated Rating Credit Suisse Neutral
2014-10-07 Upgrade Panmure Gordon Hold to Buy
2014-09-30 Reiterated Rating Deutsche Bank Hold
2014-09-29 Reiterated Rating JPMorgan Chase & Co. Underweight
2014-09-29 Reiterated Rating Jefferies Group Hold
2014-09-29 Reiterated Rating Credit Suisse Neutral
2014-09-29 Reiterated Rating Beaufort Securities Hold
2014-09-17 Reiterated Rating Deutsche Bank Hold
2014-09-16 Reiterated Rating Credit Suisse Neutral
2014-09-12 Reiterated Rating Panmure Gordon Hold
2014-09-12 Reiterated Rating JPMorgan Chase & Co. Underweight
2014-09-08 Reiterated Rating Deutsche Bank Hold
2014-09-08 Reiterated Rating Credit Suisse Neutral
2014-09-03 Reiterated Rating Panmure Gordon Hold
2014-08-22 Reiterated Rating Panmure Gordon Hold
2014-08-22 Reiterated Rating Deutsche Bank Hold
2014-08-22 Reiterated Rating Beaufort Securities Hold
2014-08-14 Reiterated Rating Credit Suisse Neutral
2014-08-04 Reiterated Rating Barclays Equal Weight
2014-07-31 Reiterated Rating Berenberg Bank Hold
2014-07-28 Reiterated Rating Panmure Gordon Hold
2014-07-24 Reiterated Rating Deutsche Bank Hold
2014-07-16 Reiterated Rating Citigroup Inc. Buy
2014-07-10 Reiterated Rating Credit Suisse Neutral
2014-07-09 Reiterated Rating Liberum Capital Buy
2014-07-04 Reiterated Rating Citigroup Inc. Buy
2014-07-03 Initiated Coverage JPMorgan Chase & Co. Underweight
2014-07-02 Reiterated Rating Deutsche Bank Hold
2014-06-20 Reiterated Rating Liberum Capital Buy
2014-06-20 Reiterated Rating Citigroup Inc. Buy
2014-06-16 Reiterated Rating Beaufort Securities Hold
2014-06-13 Reiterated Rating Deutsche Bank Hold
2014-06-11 Reiterated Rating Jefferies Group Hold
2014-06-05 Reiterated Rating BNP Paribas Neutral
2014-06-04 Reiterated Rating Credit Suisse Neutral
2014-06-03 Reiterated Rating Deutsche Bank Hold
2014-05-30 Reiterated Rating Citigroup Inc. Buy
2014-05-28 Reiterated Rating Jefferies Group Hold
2014-05-28 Reiterated Rating Beaufort Securities Hold
2014-05-27 Downgrade Kepler Capital Markets Hold to Reduce
2014-05-27 Initiated Coverage Bank of America Neutral
2014-05-27 Downgrade Societe Generale Hold to Sell
2014-05-23 Reiterated Rating Deutsche Bank Hold
2014-05-21 Reiterated Rating Barclays Equal Weight $19.00 to $20.00
2014-05-20 Reiterated Rating Liberum Capital Buy
2014-05-20 Reiterated Rating Beaufort Securities Hold
2014-05-20 Upgrade Danske Hold
2014-05-19 Reiterated Rating Prime Wealth Buy
2014-05-19 Downgrade Panmure Gordon Buy to Hold
2014-05-19 Downgrade Leerink Swann Outperform to Market Perform
2014-05-15 Reiterated Rating Credit Suisse Neutral
2014-05-14 Reiterated Rating Citigroup Inc. Buy
2014-05-12 Reiterated Rating Deutsche Bank Hold
2014-05-07 Reiterated Rating Societe Generale Hold
2014-05-07 Downgrade Beaufort Securities Hold
2014-05-05 Downgrade Danske Buy to Sell
2014-05-01 Reiterated Rating Deutsche Bank Hold
2014-04-30 Reiterated Rating Jefferies Group Hold
2014-04-30 Reiterated Rating Credit Suisse Underperform to Neutral
2014-04-29 Upgrade Panmure Gordon Hold to Buy
2014-04-29 Upgrade Kepler Capital Markets Reduce to Hold
2014-04-25 Upgrade Societe Generale Sell to Hold $50.00
2014-04-25 Reiterated Rating Barclays Equal Weight
2014-04-22 Reiterated Rating Jefferies Group Hold
2014-04-22 Reiterated Rating Deutsche Bank Hold
2014-04-22 Upgrade Credit Suisse Underperform to Neutral
2014-04-22 Upgrade Citigroup Inc. Neutral to Buy
2014-04-17 Reiterated Rating JPMorgan Chase & Co. Underweight
2014-04-01 Upgrade Panmure Gordon Sell to Hold
2014-03-13 Downgrade JPMorgan Chase & Co. Neutral to Underweight
2014-03-13 Downgrade Morgan Stanley Underweight
2014-03-03 Downgrade Bank of America Neutral to Underperform
2014-02-27 Boost Price Target Leerink Swann Outperform $34.00 to $37.50
2014-02-26 Reiterated Rating Jefferies Group Hold
2014-02-26 Reiterated Rating Galvan Research Buy
2014-01-15 Upgrade Danske Sell to Buy
2014-01-14 Upgrade Morgan Stanley Equal Weight
2014-01-14 Upgrade Leerink Swann Market Perform to Outperform $27.50 to $34.00
2014-01-09 Upgrade Jefferies Group Underperform to Hold
2013-12-20 Downgrade Bryan Garnier & Cie Buy to Neutral
2013-12-20 Boost Price Target Natixis $26.50 to $28.50
2013-11-15 Upgrade Liberum Capital Hold to Buy
2013-11-13 Downgrade Panmure Gordon Hold to Sell
2013-10-28 Upgrade Bank of America Underperform to Neutral $24.41 to $27.60
2013-10-11 Downgrade Jefferies Group Hold to Underperform
2013-09-30 Reiterated Rating Leerink Swann Market Perform
2013-09-16 Upgrade Nordea Equity Research Sell to Buy
2010-09-22 Reiterated Barclays Capital Equal Weight $225 to $230
2010-07-29 Downgrade Standpoint Research Buy to Hold $60
2010-06-30 Upgrade Jefferies Underperform to Hold
2010-01-13 Upgrade Credit Suisse Underperform to Neutral
2009-11-16 Initiated Deutsche Securities Hold
2009-11-12 Initiated Barclays Capital Equal Weight
2009-11-09 Downgrade JP Morgan Neutral to Underweight
2009-09-29 Downgrade Collins Stewart Hold to Sell
2009-08-20 Downgrade Citigroup Buy to Hold
2009-06-15 Upgrade Citigroup Hold to Buy
2009-05-14 Downgrade Jefferies & Co Hold to Underperform
2009-04-27 Upgrade UBS Neutral to Buy
2009-03-17 Initiated Credit Suisse Underperform
2009-01-30 Upgrade Deutsche Securities Hold to Buy
2009-01-30 Downgrade Citigroup Buy to Hold
2009-01-26 Initiated Jefferies & Co Hold
2008-10-29 Upgrade Cowen & Co Neutral to Outperform
2008-07-07 Downgrade Deutsche Securities Buy to Hold
2008-06-26 Downgrade HSBC Securities Neutral to Underweight
2008-04-18 Downgrade JP Morgan Neutral to Underweight
2016-07-12 Initiated Coverage Argus Hold
2016-06-27 Reiterated Rating Deutsche Bank Buy
2016-06-27 Reiterated Rating Deutsche Bank AG Buy
2016-06-25 Reiterated Rating Citigroup Inc. Buy
2016-06-16 Reiterated Rating Leerink Swann Hold $34.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments